(NASDAQ: CRSP) Crispr Therapeutics Ag's forecast annual revenue growth rate of 157.32% is forecast to beat the US Biotechnology industry's average forecast revenue growth rate of 57.08%, and it is also forecast to beat the US market's average forecast revenue growth rate of 10.39%.
Crispr Therapeutics Ag's revenue in 2025 is $37,675,000.On average, 10 Wall Street analysts forecast CRSP's revenue for 2025 to be $3,450,142,812, with the lowest CRSP revenue forecast at $207,272,842, and the highest CRSP revenue forecast at $12,350,006,812. On average, 10 Wall Street analysts forecast CRSP's revenue for 2026 to be $20,901,997,893, with the lowest CRSP revenue forecast at $224,545,578, and the highest CRSP revenue forecast at $127,792,343,215.
In 2027, CRSP is forecast to generate $62,268,734,346 in revenue, with the lowest revenue forecast at $11,175,460,710 and the highest revenue forecast at $195,717,380,681.